>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
术前同期放化疗治疗局部晚期宫颈癌的临床观察
作者:王蒙1  张蓓2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属徐州医院 妇产科, 江苏 徐州 221009
关键词:宫颈癌 局部晚期 同期放化疗 新辅助化疗 手术治疗 
分类号:R737.33;R815;R453
出版年·卷·期(页码):2013·32·第六期(713-717)
摘要:

目的:观察紫杉醇+顺铂(TP方案)新辅助化疗联合腔内后装放疗同期治疗局部晚期宫颈癌的临床疗效。方法:作者回顾性分析了48例局部晚期宫颈癌患者的临床资料,分别于术前行新辅助化疗联合腔内后装放疗(CCR组)、新辅助化疗(NACT组),通过对这些患者在治疗前后局部病灶大小的变化、毒副反应、能否实施手术及术中情况、术后病理结果等方面的对比分析,明确术前同步放化疗在宫颈癌临床治疗中的效果及其安全性。结果:CCR组局部晚期宫颈癌的治疗有效率为92.3%,明显高于NACT组68.2%的有效率(P<0.05),CCR可明显改善宫旁浸润情况,且不会增加总的毒副反应和术后并发症的发生率。结论:新辅助化疗联合腔内后装放疗在治疗局部晚期宫颈癌中是安全有效的。

Objective: To evaluate the clinical efficacy and side effects of concurrent chemoradiotherapy on locally advanced cervical cancer by compared with neoadjuvant chemotherapy (paclitaxel combined with DDP). Methods: All patients with locally advanced cervical cancer were separated into two groups: concurrent chemoradiotherapy group (CCR group) and neoadjuvant chemotherapy group (NACT group). The effect and safety were evaluated by comparing the change of the lesion size, toxic side effects, and the condition during operation, operative complications, and pathology. Results: Compared with NACT, CCR has high effective rate (92.3% vs 68.2%), and improved more in utero-tissue infiltration. But, the incidence of side effects in two groups was almost equally. There were no differences in these two groups in cervical infiltration, vaginal cutting margin infiltration, lymphatic metastasis and the incidence of postoperative complications. Conclusion: Concurrent chemoradiotherapy is a safe and effective therapeutic method for treating cervical cancer in locally advanced stage.

参考文献:

[1] 王登风,胡丽娜.宫颈癌的预防研究进展[J].肿瘤预防与治疗,2008,21(4):349-352.
[2] THERASSE P,ARBUCK S G,EISENHAUER E A,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
[3] KATSAROS D,GRIBAUDO S.The proper use of multimodality treatment in locally advanced cervical cancer[J].Gynecol Oncol,2011,121(2):422-423.
[4] 孙建衡.妇科恶性肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2002:108-109.
[5] MIZUNO K,KIDOKORO K,MIYAZAKI K,et al.Neoadjuvant chemotherapy with intra arterial infusion in the treatment of advanced cervical cancer[J].Gan To Kagaku Ryoho,2005,32(6):815-819.
[6] SELVAGGI L,LOIZZI V,di GILIO A R,et al.Neoadjuvant chemotherapy in cervical cancer:a 67 patients experience[J].Int J Gynecol Cancer,2006,16(2):631-637.
[7] 糜若然,陈星.宫颈癌新辅助化疗的评价[J].国外医学:妇产科学分册,2006,33(1):61-63.
[8] 马荣,陈曦海,耿晓星,等.术前同期放化疗对局部晚期宫颈癌近期疗效的综合评价[J].实用肿瘤学杂志,2012,26(4):314-318.
[9] 张立英,曹文淼,陈立凌,等.调强适形放疗同步紫杉醇加卡铂与同步单药顺铂方案治疗晚期宫颈鳞癌的比较研究[J].东南大学学报:医学版,2012,31(4):456-459.
[10] KIM H S,KIM J Y,PARK N H,et al.Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stageⅠB1-ⅡA cervical cancer[J].Gynecol Oncol,2012,119(2):217-224.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405763 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364